IMM 1 104
Alternative Names: IMM-1-104Latest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator Immuneering
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 12 Dec 2024 IMM 1 104 receives Fast track status from the US FDA for Malignant melanoma (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater)
- 15 Oct 2024 IMM 1 104 receives Orphan Drug status for Pancreatic cancer in USA
- 31 Jul 2024 IMM 1 104 receives Fast track status from the US FDA for Pancreatic cancer (First-line therapy or greater)